Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04091880
Other study ID # EV71-Flu-Combine-01
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date September 26, 2019
Est. completion date August 10, 2021

Study information

Verified date October 2022
Source China National Biotec Group Company Limited
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Subjects will be recruited and divided into 3 groups: 1. Experimental Group (378 subjects): combined immunization of EV71 vaccine and influenza vaccine; 2. Control Group A (378 subjects): EV71 vaccine only; 3. Control Group B (378 subjects): influenza vaccine only; All blood samples will be collected before and one month after vaccinatioin. The immunogenicity and safety of both experimental and control groups will be compared and the data be analyzed.


Description:

To further evaluate the feasibility of simultaneously administration of EV71 vaccine and flu vaccine, we design this clinical trial to test its immunogenicity and safety. 1134 subjects aged from 6 to 11 months old are divided into one experimental group and two control groups (control group A and B). 378 subjects from the experimental group will be simultaneously administrated with one dose of EV71 vaccine (0.5 ml) and one dose of influenza vaccine (0.25 ml). One month later, they are going to receive a second dose of EV71 vaccine and influenza vaccine, simultaneously. Blood samples are collected before the first vaccination, and one month following the second vaccination. 378 subjects from the control group A will be only administrated with two doses of EV71 vaccine (0.5 ml) (1 month apart). Blood samples are collected before the first vaccination, and one month following the second vaccination. 378 subjects from the control group B will be only administrated with two doses of influenza vaccine (0.25 ml) (1 month apart). Blood samples are collected before the first vaccination, and one month following the second vaccination. To evaluate the immunogenicity, we will detect and compare the neutralization antibody levels, the seroprotection rates, and antibody geometric mean concentrations. The safety of all groups will be monitored as well.


Recruitment information / eligibility

Status Completed
Enrollment 1134
Est. completion date August 10, 2021
Est. primary completion date January 6, 2020
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 6 Months to 11 Months
Eligibility Inclusion Criteria: - subjects aged from 6-11 months old at the date of recruitment; - with informed consent signed by parent(s) or guardians; - parent(s) or guardians are able to attend all planned clinical appointments and comply with all study instructions; - subjects not receive any vaccination within 14 days at the date of recruitment; - subjects have not been vaccinated with EV71 vaccine, seasonal flu vaccine; - subjects with no medical history of EV71 infection; - axillary temperature =37.0? Exclusion Criteria: - subject who has a medical history with Hypersensitiveness, eclampsia, epilepsy, cerebropathia and neurological illness; - allergic to any ingredient of vaccine or with allergy history to any vaccine; - subjects with immunodeficency or suspected impairment of immunologic function (e.g. caused by HIV), or subjects are in the process of immunosuppressor therapy(Taking orally injecting of steroid hormone); - administration of immunoglobulins within 30 days prior to this study; - acute febrile disease(temperature = 37.0°C) or infectious disease; - have a clearly diagnosed history of thrombocytopenia or other coagulopathy, - may cause contraindications for subcutaneous injection; - any serious chronic illness, acute infectious diseases, or respiratory diseases; - severe cardiovascular disease, liver and kidney diseases or diabetes mellitus with complications; - any kind of infectious, purulent, or allergic skin diseases; - any other factor that makes the investigator determines the subject is unsuitable for this study.

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
EV71 vaccine and influenza vaccine
simultaneously administrated with EV71 vaccine and influenza vaccine
EV71 vaccine
administrated with EV71 vaccine only
influenza vaccine
administrated with influenza vaccine only

Locations

Country Name City State
China Zhejiang provincial center for disease control and prevention Hangzhou Zhejiang

Sponsors (8)

Lead Sponsor Collaborator
China National Biotec Group Company Limited Changchun Institute of Biological Products Co., Ltd., Guizhou Center for Disease Control and Prevention, Henan Center for Disease Control and Prevention, National Institutes for Food and Drug Control, China, Peking University, Wuhan Institute of Biological Products Co., Ltd, Zhejiang Provincial Center for Disease Control and Prevention

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Seroconversion rate I the rate of positive seroconversion against EV71 Baseline (before vaccination) and 1 month after the last dose
Primary Seroconversion rate II the rate of positive seroconversion against Influenza A (H3N2, H1N1) and B Type viruses Baseline (before vaccination ) and 1 month after the last dose
Primary Geometric mean titer (GMT) I Measure neutralizing antibody titers against EV71 Baseline (before vaccination) and 1 month after the last dose
Primary Geometric mean titer (GMT) II Measure neutralizing antibody titers against Influenza A (H3N2, H1N1) and B Type viruses Baseline (before vaccination) and 1 month after the last dose
Secondary adverse events following vaccination analyse the numbers and rates of participants who experience adverse events following immunization 6 months
See also
  Status Clinical Trial Phase
Completed NCT05523089 - The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults Phase 2
Completed NCT05009251 - Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake N/A
Completed NCT03282240 - Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US Phase 3
Completed NCT00968526 - Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00968539 - Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults Phase 3
Completed NCT00971425 - Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1) Phase 3
Completed NCT05525494 - Patient Portal Flu Vaccine Reminders (5) N/A
Completed NCT04074928 - Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects Phase 3
Completed NCT04695717 - This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam Phase 3
Completed NCT05012163 - Lottery Incentive Nudges to Increase Influenza Vaccinations N/A
Completed NCT04109222 - Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively Phase 4
Completed NCT03888989 - Response to Influenza Vaccine During Pregnancy Phase 1
Completed NCT02587221 - Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age Phase 3
Completed NCT03453801 - The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection Phase 1
Completed NCT01440387 - A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older Phase 3
Terminated NCT01195779 - Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children Phase 2
Completed NCT03321968 - Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults Phase 3
Completed NCT00972517 - Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children Phase 3
Completed NCT04570904 - Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
Recruiting NCT03331991 - Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel N/A